IXICO PLC (LSE:IXI, OTC:PHYOF) has delivered double-digit revenue growth for the year ended 30 September, with sales rising 13% to £6.5 million, up from £5.8 million a year earlier.
The neuroscience data specialist said growth was driven by new contract wins, extensions to existing partnerships, and an expansion into adjacent market areas.
The company, which uses AI-powered imaging analytics to support drug development in neurological conditions, reported a year-end order book of £13.8 million.
While slightly lower than last year’s £15.3 million, the second half of FY25 saw momentum return, with £4.2 million in new contracts and extensions signed.
IXICO’s cash position improved significantly, standing at £3.5 million at year-end versus £1.8 million in 2024.
This reflects the impact of a £3.7 million capital raise earlier in the year, offset by strategic investment in the company’s growth initiatives.
Full-year EBITDA loss is expected to be no more than £1.6 million, slightly better than market forecasts and narrower than the £1.7 million loss recorded last year.
Management stated that the figure reflects targeted spending aimed at maintaining long-term growth.
Since the start of the new financial year, IXICO has secured a further £0.9 million in new business, adding to its positive momentum.
Chief executive Bram Goorden said the year marked a strong first full period under his leadership, highlighting the team’s ability to win new business and scale operations.
“Patients are waiting for solutions, and the biopharma industry is working harder than ever in CNS,” he said.